Identifying liver disease-specific gut microbiomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify gut microbiomes specific to patients with chronic refractory liver diseases, including autoimmune hepatitis and primary biliary cholangitis. Participants aged 19 and older, along with their household members, will provide blood and stool samples for analysis. The study will focus on understanding the gut-liver axis and its role in the pathogenesis and progression of liver diseases. The research will be conducted at Chungnam National University Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 19 years and older diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, who have consented to participate in this study at Chungnam National University Hospital.
* Adults aged 19 years and older, who are cohabitants of patients diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, and have consented to participate in this study at Chungnam National University Hospital.

B. Exclusion

Exclusion Criteria:

* Individuals under the age of 19.
* Patients or guardians who do not consent to participate in the study

Where it's running

• Chungnam National University Hospita
  Daejeon, Jung-gu, South Korea Recruiting

Study contacts

• Principal investigator: Hyuksoo Eun — Chungnam National University Hospital
• Study coordinator: Soon Ok Kim
• Email: dona3734@cnuh.co.kr
• Phone: 82-42-280-6717

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Siplizumab to prevent immune issues in liver transplant patients with autoimmune liver disease

  This study is testing if a new medication called siplizumab can help prevent immune problems in adults with autoimmune liver disease who are getting a liver transplant.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06455280

• Improving outcomes in pediatric autoimmune liver disease

  This study is trying to improve care for kids with autoimmune liver diseases by collecting and sharing information about their treatments and health to help doctors provide better support.

  Recruiting at 8 sites Children's Hospital Medical Center, Cincinnati · Palo Alto, California and 7 other locations · NCT05750498

• Biobank for cholestatic liver diseases

  This study is collecting samples and health information from people with cholestatic liver diseases to see if it can help us better understand these conditions and improve how we detect and predict them.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT03445585

• Using MRI to predict outcomes in children with autoimmune liver disease

  This study is testing if MRI scans can help predict how well children with autoimmune liver diseases will do over time.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT03178630

• Using MRI to assess liver damage in children with autoimmune liver disease

  This study is testing if MRI scans can safely show liver damage in children with autoimmune liver diseases like PSC and AIH, helping doctors understand their condition better without needing invasive tests.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT03175471

• Additive Physical Activity for Hypothyroidism in Older Women with Glaucoma and Fatty Liver

  We’re testing whether adding a treadmill-based exercise program to standard thyroid treatment helps improve health in older women who have subclinical hypothyroidism, glaucoma, and fatty liver.

  Recruiting Cairo University · Dokki, Giza Governorate · NCT07599241

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.